Overview:
Vasopressin is secreted by the pituitary gland, it is an anti-diuretic hormone acting on the kidneys and blood vessels. This hormone exhibits various physiological functions like diuresis, behavior and hemodynamic modulation. This hormone can be utilized in the treatment of abdominal roentgenography, postoperative abdominal distention, diabetes insipidus and gastrointestinal bleeding. This hormone is manufactured by Eagle Pharmaceuticals, Inc, JHP Pharmaceuticals, LLC and others, it can be administered in the form of injections.
Request For Sample Report (Including Full TOC, Table & Figures) @
https://www.coherentmarketinsights.com/insight/request-sample/4985
Market Drivers:
Rise in product launches by key players is expected to boost the growth of the U.S. vasopressin market during the forecast period. For instance, Dr. Reddy’s Laboratories declared the launch of their Desmopressin Acetate Injection USP, in May 2020. Similarly, Eagle Pharmaceuticals, Inc. declared that they have gained approval from the U.S. FDA for its new drug application (ANDA) for its 1ml vasopressin injection.
Impact of COVID – 19:
The COVID-19 pandemic has resulted in strict lockdowns being imposed in various countries around the world. The pandemic has impacted the entire supply chain of many industries, especially the healthcare industry due to lockdown being imposed in several areas. COVID-19 affected the economy of several regions as it directly impacted on the production and demand of various products and also creating disruptions in the distribution channels. All this had huge financial impact on financial markets and companies.
As, patients suffering from chronic diseases could not visit hospitals, their treatments were hampered, during the pandemic. This led the government to promote homecare settings providing these patients with safe and much more convenient solution.
Key players in the market are focusing on collaborations or partnerships which is anticipated to drive the growth of the U.S. Vasopressin market over the forecast period. For instance, Endo International plc, declared their collaboration with a U.S.-based pharmacy solutions provider, Premier for supplying vials of Vasostrict USP (vasopressin injection) to various healthcare professionals in the U.S. for maintaining critical care during the pandemic.
Get PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/4985
Key Takeaways:
Rising incidences of cardiovascular diseases like coronary artery disease and heart attack is estimated to exhibit a CAGR of 14.7% and fuel the growth of the U.S. vasopressin market during the forecast period. For instance, in 2019, American College of Cardiology Foundation, stated that around 1.05 million individuals in the United States of America have been suffering from coronary diseases.
Market players are focused on developing new variety of intravenous vasopressin injection and it is anticipated to fuel the growth if the intravenous injection segment, among type in the U.S. vasopressin market during the forecast period. For instance, a U.S. based pharmaceutical company, Par Pharmaceutical recommends an intravenous vasopressin injection, Vasostrict, which helps in increasing blood pressure in patients encountering from vasodilatory shock.
Key players:
Key players active in the U.S. vasopressin market are Otsuka Holdings Co, Pfizer Inc., Azevan Pharmaceuticals, Inc, Astellas Pharma Inc., Par Pharmaceutical, Dr. Reddy’s Laboratories Ltd and Cumberland Pharmaceuticals Inc.
Reasons to buy this U.S. Vasopressin Market Report
☑ It attempts an analysis of the competing scenario.
☑ The current and exceptional product revenue market.
☑ An in-depth data on the regional investigation and competitive landscape structure.
☑ It benefits in creating an awareness of the important key product segments.
☑ The marketing strategies, opportunities, and development factors are explained.
☑ U.S. Vasopressin market size estimation and recent advancements in the industry are explained.
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/4985
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Type
- Market Snippet, By Application
- Market Snippet, By End User
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- PEST Analysis
- Industry Trends
- Pipeline Analysis
- Epidemiology
- Reimbursement Scenario
- Regulatory Scenario
- Acquisition and Collaboration Scenario
- Market Dynamics
- U.S. Vasopressin Market – Impact of Coronavirus (Covid-19) Pandemic
- COVID-19 Epidemiology
- Impact of COVID-19 on Demand and Supply of Vasopressin
- Impact of COVID-19 on the overall Healthcare Sector
- U.S. Vasopressin Market, By Type, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Intravenous Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Intramuscular Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Subcutaneous Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- U.S. Vasopressin Market, By Application, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Anti-diuretic Hormone Deficiency
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Gastrointestinal Bleeding
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Vasodilatory Shock
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Ventricular Tachycardia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Fibrillation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- U.S. Vasopressin Market, By End User, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Dental Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Competitive Landscape
- Company Profiles
- Par Pharmaceutical*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer Inc.
- Eagle Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Cumberland Pharmaceuticals Inc.
- Dr. Reddy’s Laboratories Ltd.
- Athenex, Inc.
- Otsuka Holdings Co., Ltd
- Azevan Pharmaceuticals, Inc.
- Par Pharmaceutical*
- Company Profiles
*Key pointers provided are also applicable to other companies covered in the scope of the report.
- Section
- Research Methodology
- About Us
- Contact
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact us:
Mr. Shah
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com